Company Overview and News

 
Fairfax's Duke opens handy lead in one-year Shares Race

2018-09-22 smh.com.au
Fairfax business reporter Jennifer Duke has increased her lead in the year-long Shares Race over second-place holder Angie Ellis of 80 20 Investments, with strong performances from Nearmap, Nine Entertainment and TPG Telecom.
TPGTF TPPTY NWH TPM IEL CTD CTMLF

 
Corporate Travel Management Ltd 2018 Q4 - Results - Earnings Call Slides

2018-08-22 seekingalpha
The following slide deck was published by Corporate Travel Management Ltd in conjunction with their 2018 Q4 earnings call.
CTD CTMLF

 
Flight Centre To Hit Turbulence

2018-07-20 seekingalpha
Flight Centre's stock has risen almost 140% since 2017 despite revenue remaining stagnant over the past several years and the ever-increasing threat of a severe downturn in the Australian economy.
FGETF FLT FGHRY MS CTD CTMLF

 
Duke increases lead in year-long race with Ellis in second

2018-07-20 smh.com.au
Fairfax business reporter Jennifer Duke has increased her lead in week 24 of the year-long Shares Race, with her pick Nine Entertainment continuing to do well.
CTD CTMLF

 
Fairfax's Jennifer Duke increases lead in one-year Shares Race

2018-05-12 smh.com.au
Fairfax business reporter Jennifer Duke has increased her lead in week 14 of the year-long Shares Race, with Nine Entertainment followed by Nearmap still her best picks so far.
AVB CTD CTMLF

12
RingCentral (RNG) Q1 2018 Results - Earnings Call Transcript

2018-05-10 seekingalpha
Greetings, and welcome to the RingCentral First Quarter 2018 Earnings Conference Call. At this time, all participants are in a listen-only mode. A question-and-answer session will follow the formal presentation. As a reminder, this conference is being recorded.
RNG MS CTD CTMLF

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

Silicon Investor Message Boards

This table lists all message boards related to ASX:CTD / CORPORATE TRAVEL MANAGEMENT LIMITED on message board site Silicon Investor.

Computer Devices, Inc (CTDVB) Computer Devices, Inc (CTDVB) Computer Devices, Inc (CTDVB)